Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Straus

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expressionD A Scheinberg, D J Straus, S D Yeh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz, P A Hamlin, J Gabrilove, et al.
Leukemia & Lymphoma|September 7, 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapyG B Donnelly, J Glassman, C Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Cancer Treatment Reports|April 1, 1982
Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky diseaseC W Young, D J Straus, J Myers, et al.
Cancer|July 15, 1980
The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up reportD J Straus, J Myers, S Passe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2009
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experienceS M Edwards-Bennett, L M Jacks, C H Moskowitz, et al.
Bone Marrow Transplantation|April 27, 1999
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphomaC H Moskowitz, S D Nimer, J R Glassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Semen cryopreservation and artificial insemination for Hodgkin's diseaseJ R Redman, D R Bajorunas, M C Goldstein, et al.
The New England Journal of Medicine|June 5, 1997
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials GroupL D Kaplan, D J Straus, M A Testa, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expressionD A Scheinberg, D J Straus, S D Yeh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz, P A Hamlin, J Gabrilove, et al.
Leukemia & Lymphoma|September 7, 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapyG B Donnelly, J Glassman, C Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Cancer Treatment Reports|April 1, 1982
Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky diseaseC W Young, D J Straus, J Myers, et al.
Cancer|July 15, 1980
The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up reportD J Straus, J Myers, S Passe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2009
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experienceS M Edwards-Bennett, L M Jacks, C H Moskowitz, et al.
Bone Marrow Transplantation|April 27, 1999
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphomaC H Moskowitz, S D Nimer, J R Glassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Semen cryopreservation and artificial insemination for Hodgkin's diseaseJ R Redman, D R Bajorunas, M C Goldstein, et al.
The New England Journal of Medicine|June 5, 1997
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials GroupL D Kaplan, D J Straus, M A Testa, et al.
Pageof 9